logo
  Join        Login             Stock Quote

Johnson & Johnson (JNJ) Estimates Revised By RBC Capital After Q1, 'Sector Perform' Maintained

 April 18, 2012 03:47 PM
 


(By Balaseshan) RBC Capital Markets analyst Glenn Novarro raised his earnings estimates for Johnson & Johnson (NYSE:JNJ) while lowering revenue estimates after the company's first quarter results.

The brokerage, which maintained its "Sector Perform" rating and $65 price target, lifted its Q2-2012 adjusted EPS estimate to $1.29 from $1.26, its 2012 estimate to $5.14 from $5.09 and its 2013 estimate to $5.45 from $5.42.

The firm cut its Q2-2012 revenue estimate to $16.627 billion from $16.788 billion, its 2012 forecast to $66.485 billion from $67.048 billion and its 2013 estimate to $69.885 billion from $70.521 billion.

[Related -Can Abbvie Inc (NYSE:ABBV) Trump Gilead Sciences, Inc.'S (NASDAQ:GILD) HCV Lead?]

JNJ reported Q1 sales of $16.14 billion (down 0.2% year-over-year), $120 million lower than Street expectations of $16.3 billion and almost $200 million below Novarro's estimate. The sales miss, relative to Street expectations, was largely driven by Consumer and to a lesser extent MD&D.

On the conference call, management cited modestly positive utilization data, particular for U.S.-based hospital surgical procedural volumes. The analyst noted that JNJ receives surgical procedure data on a one-quarter lag. JNJ posted EPS of $1.37 excluding items, $0.02 ahead of the Street's $1.35 forecast and $0.05 above his estimate of $1.32.

JNJ raised 2012 sales guidance on foreign exchange and earnings guidance to reflect the Q1 beat. JNJ raised 2012 sales guidance to $66.5 billion, reflecting about 2% to 3% year-over-year reported growth (Street estimates $66.4 billion), owing to currency. JNJ raised EPS guidance to $5.07 to $5.17, to reflect the Q1 beat (Street predicts $5.11). 2012 guidance excludes the Synthes acquisition.

[Related -Johnson & Johnson (JNJ) Dividend Stock Analysis]

The analyst lowered 2012 sales forecast by about $560 million, reflecting Q1 results and a weaker MD&D and Consumer outlook. He is lowering Consumer forecast by almost $180 million to $14.9 billion (flat% year-over-year) owing to ongoing McNeil issues and supply disruptions associated with remediation efforts/Consent Decree.

For MD&D, Novarro is lowering estimate by $390 million to $26.2 billion (up 2% year-over-year) to reflect a lower U.S. outlook for Cardio Care, Ortho, and Diagnostics. He is reducing gross margin forecast by 40-basis-point to reflect increased remediation costs associated with the McNeil Consent decree, offset by lower SG&A and R&D spend.

Currently JNJ trades at about 12 times forward earnings, a about 6% premium to its large cap diversified peers. Despite JNJ's underperformance year-to-date(down 2% versus SPX up 11%), the analyst believes JNJ remains fairly valued given the company's mid-single-digit EPS outlook. He believes P/E multiple expansion is limited until the company can demonstrate high-single-digit EPS growth.

JNJ is trading down 1.50% at $63.26 on Wednesday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

For Maximum Total Return Go For Growth
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.